lower the better; the case for glucose professor taner damci istanbul university cerrahpaşa medical...

25
Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Upload: valerie-bryant

Post on 01-Jan-2016

226 views

Category:

Documents


3 download

TRANSCRIPT

Page 1: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Lower the better; the case for glucose

Professor Taner DAMCIIstanbul University Cerrahpaşa Medical

School, TURKEY

Page 2: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Epidemiology suggests high glucose is toxic

Page 3: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Blood glucose and CV risk

N = 17,869 men, aged 40–64 years; follow-up 33 years

Brunner EJ et al.Diabetes Care. 2006;29:26-31.

*Relative to baseline group of all men with blood glucose <83 mg/dL

83 mg/dL

OGTT blood glucose (mg/dL)

54 72 108 90 126 144 162 180

1.6

1.2

0.8

0.4

0.0

-0.4

CHD mortality (log hazard

ratios)*

Page 4: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B), adjusted for age, sex, and race and plotted on the log scale. All adjusted relative hazards are centered at hemoglobin A1c (HbA1c) = 5.2%, and the graphed lines are shown for the fifth to 95th percentiles of HbA1c level. The solid black line in A is from a single-knot linear spline model (knot at HbA1c = 4.6%). The dotted gray line is from a linear spline model with knots at the quintiles of HbA1c. In B, the solid black line is from a linear model; the gray dotted line is from a linear spline model with knots at the quintiles of HbA1c level. The normal range for HbA1c in persons without diabetes (4%-6%) is indicated by the dotted vertical lines in A. The current target for glycemic control in persons with diabetes (HbA1c = 7%) is indicated by the vertical dotted line in B.

Arch Intern Med. 2005 Sep 12;165(16):1910-6.

Adjusted relative hazard of coronary heart disease in 1321 individuals without diabetes (A) and 1626 individuals with diabetes (B)

Page 5: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Diabetic milleu is a toxic soup with hyperglycemia, lipids, oxidative stress and

combination of drugs….

Page 6: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Effect of postprandial hyperglycemia on the arterial wall

MealHyperglycemia

Hyperlipidemia

Haller H. Diab Res Clin Pract 1998;40:S43–S49.

Oxidative stress Endothelial damage

Atherosclerosis

Page 7: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Adjusted Hazard Ratios for Self-Reported Diagnosed Diabetes and Coronary Heart Disease, Ischemic Stroke, and Death from Any Cause, According to the Baseline Glycated Hemoglobin

Value.

Selvin E et al. N Engl J Med 2010;362:800-811.

Page 8: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

BMJ. 2006 Jan 14;332(7533):73-8. Epub 2005 Dec 21

Page 9: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Lowering glucose in a diabetic patient decreases macro and microvascular

complications.

Page 10: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Glucose Control Study Summary UKPDS

The intensive glucose control policy maintained a lower HbA1c by mean 0.9 % over a median follow up of 10 years from diagnosis of type 2 diabetes with reduction in risk of:

12% for any diabetes related endpointp=0.029

25% for microvascular endpointsp=0.0099

16% for myocardial infarctionp=0.052

24% for cataract extractionp=0.046

21% for retinopathy at twelve yearsp=0.015

33% for albuminuria at twelve yearsp=0.000054

Page 11: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Kaplan-Meier Curves for Four Prespecified Aggregate Clinical Outcomes

Holman RR et al. N Engl J Med 2008;359:1577-1589

Page 12: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

DCCT/EDIC Study Research Group.N Engl J Med. 2005;353:2643-53.

DCCT/EDIC: Intensive glucose control reduces long-term CV risk

42%(95% CI 9%–63%)

P = 0.02

57%(95% CI 12%–79%)

P = 0.02

Cumulative

incidence of any first

CV event

Cumulative

CV death,nonfatal

MI,stroke

Time (years) Time (years)

Conventional52 events

Intensive31 events

Conventional25 events

Intensive11 events

0

0.12

0.08

0.10

0.06

0.04

0.02

0 5 10 15 20

0

0.12

0.08

0.10

0.06

0.04

0.02

0 5 10 15 20

N = 1441 with type 1 diabetes

Page 13: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Glucose Control at Baseline and during Follow-up, According to Glucose-Control Strategy

The ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572

Page 14: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Cumulative Incidences of Events, According to Glucose-Control Strategy

The ADVANCE Collaborative Group. N Engl J Med 2008;358:2560-2572

Page 15: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Normoglycemia does not necessarily mean increased

hypoglycemia

Page 16: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Hypoglycemia is a side effect of treatment not of good

metabolic control

Page 17: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Annual Rates of Severe Hypoglycemia According to Treatment Assignment and Adverse Clinical Outcomes among Patients with Severe Hypoglycemia.

Zoungas S et al. N Engl J Med 2010;363:1410-1418.

Page 18: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

How about ACCORD ?

Page 19: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Kaplan–Meier Curves for the Primary Outcome and Death from Any Cause.

The Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008;358:2545-2559.

Page 20: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Spline curves displaying the risk of all-cause mortality with the two treatment strategies over the range of average A1C from 6.0 to 9.0%. The curves represent the linear part of the proportional hazards models derived from values for intervals of average A1C from model 3. For clarity, the figure omits values <6 and >9%; 5% of deaths are excluded from this plot at the lower end and also at the ∼higher end of the A1C range, but these data are included in the models. The bold orange line represents the intensive treatment strategy group, the bold blue line represents the standard group, and the finer colored lines represent the 95% CIs for each group.

Page 21: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY
Page 22: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

Change in HbA1c by group; two subsets can be created based on likely improvement

Can we predict future improvement in glycaemic control?.Diabetic Medicine 25 (2), 170-173 2008

Page 23: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

It is inappropriately intensive treatment “not good glycemic control” which increase the risk.

Page 24: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

We have to individualize diabetes treatment. Most of the time side effects

are a result of confectionary treatments.

Page 25: Lower the better; the case for glucose Professor Taner DAMCI Istanbul University Cerrahpaşa Medical School, TURKEY

So we should achive as low HbA1c as possible in

an individual patient without causing

hypoglycemia and weight gain.

We have the tools.